Efficacy of Dose Escalation of XXXX for the Treatment of Lower Urinary Tract Symptoms.

@entity1 @entity9940
OBJECTIVES: The aim of this study was to compare the efficacy of low (0.2 mg) and intermediate (0.4 mg) dose @entity9940 in treating lower urinary tract symptoms (LUTS). METHODS: @entity1 were treated with low-dose @entity9940 for an initial run-in period of 12 weeks, then divided into two groups based on their clinical improvement. @entity1 were measured for objective parameters of peak flow rate and postvoid residual urine volume, as well as subjective symptom scores and perceived @entity1 benefit of treatment. The items were then integrated as the LUTS Outcome Score to determine dose increase or maintenance. Overall outcome was determined at 36 weeks. RESULTS: One hundred and seventy-four @entity1 were enrolled and started on 0.2 mg @entity9940 treatment. One hundred and fifty-five @entity1 completed the 36-week study. Sixty @entity1 required dose increase to 0.4 mg at the 12th week. Baseline characteristics showed that a @entity1 who would benefit from 0.4 mg dosage had higher age, daytime frequency, and lower peak urine flow rate. @entity1 receiving both 0.2 and 0.04 mg both showed improved clinical outcome measures. Higher improvement was found in voiding component symptom scores and urine flow rate improvement in @entity1 receiving an increased dose. CONCLUSION: Both low- and intermediate-dose @entity9940 are effective treatment regimens. Increasing from low to intermediate dose should follow assessment of both objective and subjective improvements.
